COMMUNIQUÉS West-GlobeNewswire

-
iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
25/07/2025 -
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
25/07/2025 -
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
25/07/2025 -
GUERBET : Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte du 23 mai 2025
25/07/2025 -
Wellcome Photography Prize 2025: Winning Images Reveal Powerful Stories of Science and Health
25/07/2025 -
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
25/07/2025 -
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
25/07/2025 -
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
25/07/2025 -
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
25/07/2025 -
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
25/07/2025 -
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
25/07/2025 -
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
25/07/2025 -
La Commission européenne approuve DARZALEX® (daratumumab) comme premier traitement autorisé pour les patients présentant un myélome multiple indolent à haut risque
25/07/2025 -
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
25/07/2025 -
Cronos Group Inc. to Hold 2025 Second Quarter Earnings Conference Call on August 7, 2025
25/07/2025 -
Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
25/07/2025 -
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
25/07/2025 -
Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
25/07/2025 -
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
25/07/2025
Pages